الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Background: Accumulating evidence obviously supports the superiority of weight loss surgery over non-surgical treatments for management of morbidly obese patients in terms of outcomes as sustained weight loss, improved quality of life and prevention, reduction, or resolution of co-morbidities (e.g., Type 2 Diabetes Mellitus, dyslipidemia), as well as reduced overall mortality.
Objective: To compare Type 2 DM remission as well as the metabolic effects of 2 types of bariatric surgery; Single Anastomosis Duodeno-ileal Bypass-Sleeve (SADI-S) and One Anastomosis-Gastric bypass (OAGB), in the first year postoperative follow up in relation to DiaRem Scoring system.
Methodology: This is a prospective randomized clinical trial study conducted in Ain-Shams University Hospitals bariatric surgery unit over 40 patients with minimal follow-up of 16 months. 2 groups of patients; group A: composed of 20 patients that undergoing OAGB as a metabolic surgery for control of Type 2 DM. group B: composed of 20 patients that undergoing SADI-S as a metabolic surgery for control of Type 2 DM.
Results: Our study found that resolution of DM in SADIS patients initially occurred in 75% after 12 months increased to 80% after 15 months. However, in MGB patients it was 60% after 12 months and reached 65% after 15 months. Remission rates of SADIS patients under oral therapy is about 100% while MGB patients it was 92.3%, whereas patients under insulin therapy the number markedly goes down with shift to oral therapy or marked decrease in insulin requirements to control D.M.
Conclusion: No statistical significant difference between both groups as regard remission of DM The main determinant noticed during the study influencing remission is the duration of DM and preoperative C-peptide level-in addition to HBA1C level-and both were included later in ABCD scoring system. ABCD scoring system is more sensitive than DIAREM scoring system as regard predicting remission of DM. We recommend OAGB as a metabolic surgery for patients with early onset DM type II with BMI ranging from 30-40 The study needs to be repeated over larger sample size and longer duration to determine the long term effects of metabolic surgery.